Dr. Anson Cheung

St. Paul's Hospital's Dr. Webb and Dr. Cheung comment on COSIRA Study

Neovasc Inc. (TSXV: NVC) today reported that final data from its COSIRA trial assessing the efficacy and safety of the Neovasc ReducerTM, a novel percutaneous device for the treatment of refractory angina, was presented on March 29, 2014 in a Featured Clinical Research Presentation at ACC.14, the American College of Cardiology 63rd Annual Scientific Session & Expo.

Subscribe to RSS - Dr. Anson Cheung